119 related articles for article (PubMed ID: 38127337)
1. Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological Outcomes.
Hazen SJA; Sluckin TC; Intven MPW; Beets GL; Beets-Tan RGH; Borstlap WAA; Buffart TE; Buijsen J; Burger JWA; van Dieren S; Furnée EJB; Geijsen ED; Hompes R; Horsthuis K; Leijtens JWA; Maas M; Melenhorst J; Nederend J; Peeters KCMJ; Rozema T; Tuynman JB; Verhoef C; de Vries M; van Westreenen HL; de Wilt JHW; Zimmerman DDE; Marijnen CAM; Tanis PJ; Kusters M;
JAMA Oncol; 2024 Feb; 10(2):202-211. PubMed ID: 38127337
[TBL] [Abstract][Full Text] [Related]
2. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
3. Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study.
Stijns RCH; de Graaf EJR; Punt CJA; Nagtegaal ID; Nuyttens JJME; van Meerten E; Tanis PJ; de Hingh IHJT; van der Schelling GP; Acherman Y; Leijtens JWA; Bremers AJA; Beets GL; Hoff C; Verhoef C; Marijnen CAM; de Wilt JHW;
JAMA Surg; 2019 Jan; 154(1):47-54. PubMed ID: 30304338
[TBL] [Abstract][Full Text] [Related]
4. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial.
Rullier E; Vendrely V; Asselineau J; Rouanet P; Tuech JJ; Valverde A; de Chaisemartin C; Rivoire M; Trilling B; Jafari M; Portier G; Meunier B; Sieleznieff I; Bertrand M; Marchal F; Dubois A; Pocard M; Rullier A; Smith D; Frulio N; Frison E; Denost Q
Lancet Gastroenterol Hepatol; 2020 May; 5(5):465-474. PubMed ID: 32043980
[TBL] [Abstract][Full Text] [Related]
5. Early local recurrence and one-year mortality of rectal cancer after restricting the neoadjuvant therapy regime.
Tersteeg JJC; van Esch LM; Gobardhan PD; Kint PAM; Rozema T; Crolla RMPH; Schreinemakers JMJ
Eur J Surg Oncol; 2019 Apr; 45(4):597-605. PubMed ID: 30583821
[TBL] [Abstract][Full Text] [Related]
6. A national strategic change in treatment policy for rectal cancer--implementation of total mesorectal excision as routine treatment in Norway. A national audit.
Wibe A; Møller B; Norstein J; Carlsen E; Wiig JN; Heald RJ; Langmark F; Myrvold HE; Søreide O;
Dis Colon Rectum; 2002 Jul; 45(7):857-66. PubMed ID: 12130870
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Modified FOLFOXIRI With Selective Radiotherapy in Locally Advanced Rectal Cancer: Long-term Outcomes of Phase II Study and Propensity-Score-Matched Comparison With Chemoradiotherapy.
Zhang J; Li J; Huang M; Xie X; Cai Y; Hu H; Ling J; Wu Z; Deng Y
Dis Colon Rectum; 2023 Jul; 66(7):934-945. PubMed ID: 35834598
[TBL] [Abstract][Full Text] [Related]
8. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
[TBL] [Abstract][Full Text] [Related]
9. Treatment of clinical T1 rectal cancer in the Netherlands; a population-based overview of clinical practice.
Verseveld M; Verver D; Noordman BJ; Pouwels S; Elferink MAG; de Graaf EJR; Verhoef C; Doornebosch PG; de Wilt JHW
Eur J Surg Oncol; 2022 May; 48(5):1153-1160. PubMed ID: 34799230
[TBL] [Abstract][Full Text] [Related]
10. Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients.
Law WL; Chu KW
Ann Surg; 2004 Aug; 240(2):260-8. PubMed ID: 15273550
[TBL] [Abstract][Full Text] [Related]
11. [Local recurrence and survival rate after rectal cancer operations and multimodal therapy].
Thomschke D; Kyau-Ummen B; Halbfass HJ
Chirurg; 2002 Mar; 73(3):245-54. PubMed ID: 11963499
[TBL] [Abstract][Full Text] [Related]
12. Oncologic and survival outcomes in elderly patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy and total mesorectal excision.
He F; Chen M; Xiao WW; Zhang Q; Liu Y; Zheng J; Wan XB; Gao YH
Jpn J Clin Oncol; 2021 Aug; 51(9):1391-1399. PubMed ID: 34155513
[TBL] [Abstract][Full Text] [Related]
13. [Safety and prognosis analysis of transanal total mesorectal excision versus laparoscopic mesorectal excision for mid-low rectal cancer].
Sun R; Cong L; Qiu HZ; Lin GL; Wu B; Niu BZ; Sun XY; Zhou JL; Xu L; Lu JY; Xiao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):522-530. PubMed ID: 35754217
[No Abstract] [Full Text] [Related]
14. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
[TBL] [Abstract][Full Text] [Related]
15. Preoperative radiotherapy combined with intraoperative radiotherapy improve results of total mesorectal excision in patients with T3 rectal cancer.
Pacelli F; Di Giorgio A; Papa V; Tortorelli AP; Covino M; Ratto C; Bossola M; Valentini V; Sofo L; Miccichè F; Gambacorta MA; Doglietto GB
Dis Colon Rectum; 2004 Feb; 47(2):170-9. PubMed ID: 15043286
[TBL] [Abstract][Full Text] [Related]
16. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.
Bach SP; Gilbert A; Brock K; Korsgen S; Geh I; Hill J; Gill T; Hainsworth P; Tutton MG; Khan J; Robinson J; Steward M; Cunningham C; Levy B; Beveridge A; Handley K; Kaur M; Marchevsky N; Magill L; Russell A; Quirke P; West NP; Sebag-Montefiore D;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):92-105. PubMed ID: 33308452
[TBL] [Abstract][Full Text] [Related]
17. Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer.
Kulu Y; Tarantino I; Billeter AT; Diener MK; Schmidt T; Büchler MW; Ulrich A
Ann Surg Oncol; 2016 Jan; 23(1):106-13. PubMed ID: 26305025
[TBL] [Abstract][Full Text] [Related]
18. Hospital volume and outcome in rectal cancer patients; results of a population-based study in the Netherlands.
Hagemans JAW; Alberda WJ; Verstegen M; de Wilt JHW; Verhoef C; Elferink MA; Burger JWA
Eur J Surg Oncol; 2019 Apr; 45(4):613-619. PubMed ID: 30600101
[TBL] [Abstract][Full Text] [Related]
19. Comparing neoadjuvant therapy followed by local excision to total mesorectal excision in the treatment of early stage rectal cancer: a systematic review and meta-analysis of randomised clinical trials.
Lynch P; Ryan OK; Donnelly M; Ryan ÉJ; Davey MG; Reynolds IS; Creavin B; Hanly A; Kennelly R; Martin ST; Winter DC
Int J Colorectal Dis; 2023 Nov; 38(1):263. PubMed ID: 37924372
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
